HeartBeam Inc. (NASDAQ: BEAT) announced it is commencing an underwritten public offering of common stock shares. The medical technology company stated that all securities in the proposed offering will be sold by HeartBeam.

The offering is subject to market and other conditions, and there is no assurance regarding whether or when it may be completed, or the actual size or terms, according to the company's statement.

HeartBeam plans to use net proceeds to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, develop its extended-wear patch and heart attack detection initiatives, enhance AI capabilities, and for working capital and general corporate purposes.

Titan Partners, a division of American Capital Partners, is serving as the sole bookrunner for the proposed offering.

The offering is being conducted pursuant to a shelf registration statement on Form S-3/A filed with the Securities and Exchange Commission on February 9, 2026, as amended, and declared effective by the SEC on March 17, 2026.

HeartBeam develops cardiac monitoring technology, including a cable-free device designed to collect ECG signals in 3D and synthesize them into a 12-lead ECG. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025. The company holds over 20 issued patents related to its technology.